Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of paroxysmal supraventricular tachycardia (PSVT).
The Company employs a lean and cost efficient model which has the effect of minimizing overhead and focusing spending on the programs. It has assembled a core seasoned management team with expertise in cardiovascular clinical drug development, regulatory affairs, chemistry and manufacturing, and commercial preparedness which is guided by world-class key opinion leaders (KOLs) and advisors.
Net income (Q2, 2020)
EBIT (Q2, 2020)
Market capitalization (26-Feb-2021)
Closing stock price (26-Feb-2021)
When was Milestone Pharmaceuticals founded?
Milestone Pharmaceuticals was founded in 2005.
Who are Milestone Pharmaceuticals key executives?
Milestone Pharmaceuticals's key executives are Joseph Oliveto, Philippe Douville and Robert J. Wills.
How many employees does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 30 employees.
Who are Milestone Pharmaceuticals competitors?
Competitors of Milestone Pharmaceuticals include Biogen, Inovio Pharmaceuticals and MyoKardia.
Where is Milestone Pharmaceuticals headquarters?
Milestone Pharmaceuticals headquarters is located at 420 1111 Boulevard Dr.-Frederik-Philips, Montréal.
Where are Milestone Pharmaceuticals offices?
Milestone Pharmaceuticals has offices in Montréal and Charlotte.
How many offices does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 2 offices.
Receive alerts for 300+ data fields across thousands of companies